Fujifilm’s Chinese pharma patent licensing deal marks a milestone in its IP-driven transformation
Fujifilm announced this week that it had entered into a patent licensing agreement with Chinese company Zhejiang Hisun Pharmaceutical – a transaction that represents the latest step in its realignment as a life sciences-focused business.
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.